CD33 and acute myeloid leukemia: For example, whilst CD33‐positive acute myelogenous leukaemia tumors express relatively low levels of target antigen (5000–10 000 receptors per cell), an ADC that targets the CD33 antigen still shows meaningful clinical response rates.36